



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 8, 2014

Via E-mail

Nevan Elam  
Chief Executive Officer  
AntriaBio, Inc.  
890 Santa Cruz Avenue  
Menlo Park, CA 94025

**Re: AntriaBio, Inc.  
Preliminary Proxy Statement on Schedule 14C  
Filed March 31, 2014  
File No. 000-54495**

Dear Mr. Elam:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

*/s/ Daniel Greenspan for*

Jeffrey P. Riedler  
Assistant Director

cc: Via E-mail  
Anthony W. Epps  
Dorsey & Whitney LLP  
1400 Wewatta Street  
Suite 400  
Denver, CO 80202-5549